Teva Pharmaceutical Industries Ltd. In Turmoil, Plans To Cut 11% Of Its Workforce After Passover

With its executive suite in turmoil, its flagship drug under attack and its books burdened by debt following years of drought in its R&D arm, TEVA is reportedly preparing to unleash a major reorganization that will cost thousands of jobs.